Spirastrellolide A, an antimitotic macrolide isolated from the Caribbean marine sponge Spirastrella coccinea

Journal of the American Chemical Society

Volumn 125, Issue 18, 2003, Pages 5296-5297

  Williams, David E ^a   Roberge, Michel ^a   Van Soest, Rob ^b   Andersen, Raymond J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MACROLIDE; NATURAL PRODUCT; NAVELBINE; PACLITAXEL; SPIRASTRELLOLIDE A; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CARIBBEAN ISLANDS; CHEMICAL ANALYSIS; CORRELATION ANALYSIS; DRUG ISOLATION; EXTRACTION; MITOSIS INHIBITION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SPIRASTRELLA COCCINEA; SPONGE (PORIFERA); STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; MACROLIDES; MOLECULAR CONFORMATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PORIFERA;

EID: 0038631823     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0348602     Document Type: Article

References (15)

1. (a) Hamel, E. Med. Res. Rev. 1996, 16, 207.
2. (b) Allen, S. L.; Villalona-Calero, M.; Jakimowicz, K.; Fram, R.; O'Mara, V.; Kolitz, J. E.; Gallagher, M. A.; Van Echo, D.; Fischkoff, S.; O'Dwyer, P. Proc. Am. Assoc. Cancer Res. 1997, 38, 222.
3. (c) Hamel, E. Biopolymers 2002, 66, 142.
4. (d) Hood, K. A.; West, L. M.; Rouwe, B.; Northcote, P. T.; Berridge, M. V.; Wakefield, S. J.; Miller, J. H. Cancer Res. 2002, 62, 3356.
5. (e) Mooberry, S. L.; Tien, G.; Hernadez, A. H.; Plubrukarn, A.; Davidson, B. S. Cancer Res. 1999, 59, 653.
6. (f) Luduena, R. F.; Roach, M. C.; Prasad, V.; Pettit, G. R. Biochem. Pharmacol. 1993, 45, 421.
7. (a) Nieman, J. A.; Coleman, J. E.; Wallace, D. J.; Piers, E.; Lim, L. L.; Roberge, M.; Andersen, R. J. J. Nat. Prod. 2003, 66, 183.
8. (b) Cinel, B.; Roberge, M.; Behrisch, H.; van Ofwegen, L.; Castro, C. B.; Andersen, R. J. Org. Lett. 2000, 2, 257.
9. (c) Anderson, H. J.; Coleman, J. E.; Andersen, R. J.; Roberge, M. Cancer Chemother. Pharmacol. 1997, 39, 223.
10. (d) Rundle, N. T.; Xu, L.; Andersen, R. J.; Roberge, M. J. Biol. Chem. 2001, 276, 48231.
11. Roberge, M.; Cinel, B.; Anderson, H. J.; Lim, L.; Jiang, X.; Xu, L.; Kelly, M. T.; Andersen, R. J. Cancer Res. 2000, 60, 5052.
12. (a) Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R.; Schmidt, J. M.; Hooper, J. N. A. J. Org. Chem. 1993, 58, 1302.
13. (b) Kobayashi, M.; Aoki, S.; Sakai, H.; Kawazoe, K.; Kihara, N.; Sasaki, T.; Kitagawa, I. Tetrahedron Lett. 1993, 34, 2795.
14. (c) Fusetani, N.; Shinoda, K.; Matsunaga, S. J. Am. Chem. Soc. 1993, 115, 3977.
15. Complete details of the biological activity will be reported elsewhere.